| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
PCR Stock Overview
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally.
PCC Rokita Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł95.90 |
| 52 Week High | zł102.60 |
| 52 Week Low | zł56.40 |
| Beta | 1.23 |
| 1 Month Change | 7.75% |
| 3 Month Change | 4.24% |
| 1 Year Change | 70.04% |
| 3 Year Change | 14.71% |
| 5 Year Change | 42.45% |
| Change since IPO | 189.20% |
Recent News & Updates
We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
Why PCC Rokita SA (WSE:PCR) Could Be Worth Watching
PCC Rokita SA ( WSE:PCR ), is not the largest company out there, but it led the WSE gainers with a relatively large...
Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?
In this article we are going to estimate the intrinsic value of PCC Rokita SA ( WSE:PCR ) by taking the expected future...
Shareholder Returns
| PCR | PL Chemicals | PL Market | |
|---|---|---|---|
| 7D | 0.4% | 3.2% | 1.8% |
| 1Y | 70.0% | 11.5% | 18.7% |
Return vs Industry: PCR exceeded the Polish Chemicals industry which returned 11.5% over the past year.
Return vs Market: PCR exceeded the Polish Market which returned 18.7% over the past year.
Price Volatility
| PCR volatility | |
|---|---|
| PCR Average Weekly Movement | 3.9% |
| Chemicals Industry Average Movement | 3.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in PL Market | 11.5% |
| 10% least volatile stocks in PL Market | 3.5% |
Stable Share Price: PCR is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PCR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1,678 | Wieslaw Klimkowski | https://www.pcc.rokita.pl |
PCC Rokita SA manufactures and distributes chemical products in Poland and internationally. The company offers chloralkali, raw materials, and intermediates; polyurethanes; specialty products; and surfactants products, as well as polyols, naphthalene, and phosphorus derivatives. It serves adhesives, agrochemicals, building and construction, case, chemical reagents, detergents, fire prevention, food and fuel industry, furniture, I&I cleaning, lubricants and metalworking fluids, base oils, metallurgical, mining and drilling, oilfield, packaging, paints and coatings, personal care, pharmaceuticals, plastics, power, printing ink, pulp and paper, raw materials and intermediates, refrigeration and household appliances, sports and recreation, tanning and textile, transportation, vehicle cleaning and care, and water and wastewater treatment industries.
PCC Rokita Fundamentals Summary
| PCR fundamental statistics | |
|---|---|
| Market Cap | zł1.90b |
| Earnings (TTM) | zł294.33m |
| Revenue (TTM) | zł2.03b |
6.5x
P/E Ratio0.9x
P/S RatioIs PCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCR income statement (TTM) | |
|---|---|
| Revenue | zł2.03b |
| Cost of Revenue | zł1.40b |
| Gross Profit | zł631.51m |
| Expenses | zł337.18m |
| Earnings | zł294.33m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.83 |
| Gross Margin | 31.16% |
| Net Profit Margin | 14.52% |
| Debt/Equity Ratio | 68.2% |
How did PCR perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield25%
Payout RatioValuation
Is PCC Rokita undervalued compared to its fair value and its price relative to the market?
6.47x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PCR (PLN95.9) is trading above our estimate of fair value (PLN89.44)
Significantly Below Fair Value: PCR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PCR is good value based on its PE Ratio (6.5x) compared to the Polish Chemicals industry average (11.8x).
PE vs Market: PCR is good value based on its PE Ratio (6.5x) compared to the Polish market (12.3x).
Price to Earnings Growth Ratio
PEG Ratio: PCR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PCR is overvalued based on its PB Ratio (2x) compared to the PL Chemicals industry average (1x).
Future Growth
How is PCC Rokita forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-33.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PCR's earnings are forecast to decline over the next 3 years (-33.1% per year).
Earnings vs Market: PCR's earnings are forecast to decline over the next 3 years (-33.1% per year).
High Growth Earnings: PCR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PCR's revenue is expected to decline over the next 3 years (-3.9% per year).
High Growth Revenue: PCR's revenue is forecast to decline over the next 3 years (-3.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PCR's Return on Equity is forecast to be low in 3 years time (13.4%).
Past Performance
How has PCC Rokita performed over the past 5 years?
-4.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCR has high quality earnings.
Growing Profit Margin: PCR's current net profit margins (14.5%) are higher than last year (5.2%).
Past Earnings Growth Analysis
Earnings Trend: PCR's earnings have declined by 4.3% per year over the past 5 years.
Accelerating Growth: PCR's earnings growth over the past year (301.4%) exceeds its 5-year average (-4.3% per year).
Earnings vs Industry: PCR earnings growth over the past year (301.4%) exceeded the Chemicals industry 35.7%.
Return on Equity
High ROE: PCR's Return on Equity (31%) is considered high.
Financial Health
How is PCC Rokita's financial position?
Financial Position Analysis
Short Term Liabilities: PCR's short term assets (PLN633.2M) exceed its short term liabilities (PLN478.8M).
Long Term Liabilities: PCR's short term assets (PLN633.2M) do not cover its long term liabilities (PLN751.5M).
Debt to Equity History and Analysis
Debt Level: PCR's net debt to equity ratio (49.1%) is considered high.
Reducing Debt: PCR's debt to equity ratio has increased from 63.3% to 68.2% over the past 5 years.
Debt Coverage: PCR's debt is well covered by operating cash flow (72.3%).
Interest Coverage: PCR's interest payments on its debt are well covered by EBIT (16.7x coverage).
Balance Sheet
Dividend
What is PCC Rokita current dividend yield, its reliability and sustainability?
3.83%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PCR's dividend (3.83%) is higher than the bottom 25% of dividend payers in the Polish market (2.24%).
High Dividend: PCR's dividend (3.83%) is low compared to the top 25% of dividend payers in the Polish market (6.72%).
Stability and Growth of Payments
Stable Dividend: PCR has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: PCR's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.8%), PCR's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PCR's dividends in 3 years are forecast to be covered by earnings (81.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
12.0yrs
Average management tenure
CEO
Wieslaw Klimkowski
17yrs
Tenure
zł4,899,000
Compensation
Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski served as Director of Investor Supervision & Group Development of PCC Rokit...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD1.23M) is above average for companies of similar size in the Polish market ($USD322.51K).
Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: PCR's management team is seasoned and experienced (12 years average tenure).
Board Members
Experienced Board: PCR's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PCC Rokita SA's employee growth, exchange listings and data sources
Key Information
- Name: PCC Rokita SA
- Ticker: PCR
- Exchange: WSE
- Founded: NaN
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: zł1.904b
- Shares outstanding: 19.85m
- Website: https://www.pcc.rokita.pl
Number of Employees
Location
- PCC Rokita SA
- ul. Sienkiewicza 4
- Brzeg Dolny
- 56-120
- Poland
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/16 18:04 |
| End of Day Share Price | 2022/01/14 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.